Dashboard: Filter Bricks
Main page content
This report provides key findings from the 2022 National Survey on Drug Use and Health (NSDUH) on substance use, mental health, and treatment among the noninstitutionalized U.S. population aged 12 or older. Estimates are presented by age group and by race/ethnicity for selected measures.
Read key findings from the 2021 National Survey on Drug Use and Health (NSDUH) on substance use, mental health, and treatment. Metrics in the report cover the civilian, noninstitutionalized US population ages 12 and older. Estimates are presented by age group and by race/ethnicity for selected measures. Unlike other NSDUH Annual National Reports, the 2021 report has no discussion of trends over time, because changes in survey methodology mean the indicators are not comparable to past NSDUH estimates.
This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.
A guide for community leaders to use when planning to implement the “Talk. They Hear You.” campaign in their communities. The guide offers best practices and step-by-step guidance for using the campaign.
A guide for community leaders to use when planning events on underage drinking and substance use prevention for parents and caregivers, educators, and other adult role models. The guide offers best practices and sample materials for planning successful events.
A guide for community leaders to use when working with the media to promote underage drinking and substance use prevention resources for parents and caregivers, educators, and other adult role models. The guide offers best practices and sample materials for engaging the media.
The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
Displaying 1 - 10 out of 104